Recent advances in multidisciplinary management of hepatocellular carcinoma

Gomaa, Asmaa

doi:10.4254/wjh.v7.i4.673

Cited by 80 publications

(63 citation statements)

References 170 publications

(181 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the most recent data, it is associated with 5-year survival rates up to 70% and 2% to 3% perioperative mortality in patients with cirrhosis. Moreover, some authors report 5-year survival rates above 50% in patients undergoing resection for a single lesion ≤5 cm, or up to three lesions ≤3 cm each [Milan criteria (45)] but who were not fit for transplantation (46). As previously reported, laparoscopic technique with an accurate ultrasound examination of liver parenchyma can allow for a complete exclusion of hepatic lesions undetectable at the preoperative imaging and provides the minimal onset of adhesions, which is extremely useful in patients undergoing liver transplantation (47).…”

Section: Discussionmentioning

confidence: 99%

“…As previously reported, laparoscopic technique with an accurate ultrasound examination of liver parenchyma can allow for a complete exclusion of hepatic lesions undetectable at the preoperative imaging and provides the minimal onset of adhesions, which is extremely useful in patients undergoing liver transplantation (47). However, liver transplantation performed in patients fulfilling the Milan criteria results in a 5-year overall survival rate of 75%, with a risk of recurrence of <15%, with perioperative mortality and 1-year mortality of approximately 3% and ≤10%, respectively (46). As a matter of fact, liver transplantation is the most effective therapy for cirrhosis, the underlying liver disease that causes HCC (48).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Evolving Role of Local Treatments for HCC in the Third Millennium

Magistri

Tarantino

Ballarin

et al. 2017

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Evolving Role of Local Treatments for HCC in the Third Millennium

Magistri

Tarantino

Ballarin

et al. 2017

View full text Add to dashboard Cite

“…Clinical presentations may vary for patients with HCC . While most patients with early‐stage disease are asymptomatic, others may show symptoms characteristic of liver disease (ie, abdominal pain and/or swelling, weight loss, weakness, loss of appetite, jaundice, fever, and liver enlargement) .…”

Section: Current Treatment Modalities For Unresectable (Intermediate mentioning

confidence: 99%

Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres

et al. 2017

View full text Add to dashboard Cite

To identify relevant publications, the PubMed database was queried using one or more of the following search terms alone or in combination with Boolean operators: epidemiology, hepatocellular, hepatocellular cancer, hepatocellular carcinoma, unresectable, radioembolisation, selective internal radiation therapy, SIR-Spheres, yttrium 90, TACE, and sorafenib. The results were sorted or filtered by "Author", "Publication dates" or "Article types" to identify articles relevant to each section of the review. To ensure that information on ongoing clinical trials involving Y-90 resin was included, we conducted a search on "ClinicalTrials.gov", by combining the search terms "HCC" OR "hepatocellular carcinoma" with "Y 90" OR "yttrium 90" OR "radioembo", and screened for studies that involved treatment with Y-90 resin microspheres.

show abstract

“…The minimal critical remnant liver volume for safe resection is approximately 25% (15%-40%) for patients without cirrhosis and 50% (25%-90%) for patients with cirrhotic livers [24] . If the estimated remnant liver volume is less than the minimal required, preoperative portal vein embolization with the intent to divert portal flow to the non-affected lobe could be tried to lead to compensatory hypertrophy of the non-embolized liver [25] .…”

Section: Ng Standardmentioning

confidence: 99%

Hepatocellular carcinoma treatment strategies – a case-based review

Alves

Gomes

Macedo

et al. 2015

JST

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common tumors worldwide and one of the fastest growing causes of cancer-related mortality, being mostly diagnosed in patients with cirrhosis. Despite the recent efforts regarding an earlier diagnosis, the majority of patients are at advanced stages at first presentation, when the potential for institution of curative strategies is scarce. This tumor is remarkable because it occurs mostly superimposed on chronic liver diseases, which entails the need to take special attention to liver function preservation and hepatotoxicity prevention when choosing a specific therapy. Major changes had occurred in the management of HCC in the last decade. The decision-making process must be based on an accurate staging of the patient, using the Barcelona Clinic Liver Cancer (BCLC) staging system, updated knowledge of the new therapeutic options, their contraindications and the potential local or systemic complications. The authors start from 4 clinical different scenarios, in order to objectively discuss the therapeutic options available and the decision-making-process based on the staging system.

show abstract

Recent advances in multidisciplinary management of hepatocellular carcinoma

Cited by 80 publications

References 170 publications

The Evolving Role of Local Treatments for HCC in the Third Millennium

The Evolving Role of Local Treatments for HCC in the Third Millennium

Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres

Hepatocellular carcinoma treatment strategies – a case-based review

Contact Info

Product

Resources

About